Preventive Cardiovascular Measures in Children with Elevated Blood Pressure
Abstract
:1. Introduction
2. Elevated Blood Pressure in Children
- –
- Normal BP;
- –
- Elevated BP (not defined in Hypertension Canada’s 2020 guidelines);
- –
- Stage 1 hypertension;
- –
- Stage 2 hypertension.
3. Cardiovascular Risk Factors in Childhood
4. Preventive Cardiovascular Measures in Childhood Hypertension
5. Primordial and Primary Prevention
6. Secondary Prevention
7. Tertiary Prevention
8. Quaternary Prevention
- ▪
- Avoiding overdiagnosis: Ensuring that hypertension diagnosis is accurate and not based on isolated high readings or non-standardised measurements.
- ▪
- Judicious use of medications: Preventing unnecessary pharmacotherapy by first exploring and implementing lifestyle modifications such as diet and exercise before resorting to medication.
- ▪
- Minimising unnecessary tests: Avoiding excessive diagnostic tests that do not contribute to the management or outcome of the condition, reducing the physical and psychological burden on the child.
- ▪
- Education and communication: Educating families about the importance of lifestyle changes and the potential risks of unnecessary treatments, fostering informed decision making.
- ▪
- Monitoring and follow-up: Regularly reviewing the necessity and effectiveness of any prescribed treatments, ensuring that interventions remain appropriate and are not continued longer than necessary.
- ▪
- Preventing medicalisation: Focusing on holistic approaches that consider the child’s overall well-being rather than solely treating the medical condition, thereby avoiding the medicalisation of normal variations in BP.
9. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- GBD 2021 Causes of Death Collaborators. Global Burden of 288 Causes of Death and Life Expectancy Decomposition in 204 Countries and Territories and 811 Subnational Locations, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet 2024, 403, 1988. [Google Scholar] [CrossRef]
- Andersson, C.; Vasan, R.S. Epidemiology of Cardiovascular Disease in Young Individuals. Nat. Rev. Cardiol. 2018, 15, 230–240. [Google Scholar] [CrossRef] [PubMed]
- Lurbe, E.; Agabiti-Rosei, E.; Cruickshank, J.K.; Dominiczak, A.; Erdine, S.; Hirth, A.; Invitti, C.; Litwin, M.; Mancia, G.; Pall, D.; et al. 2016 European Society of Hypertension Guidelines for the Management of High Blood Pressure in Children and Adolescents. J. Hypertens. 2016, 34, 1887–1920. [Google Scholar] [CrossRef] [PubMed]
- Di Bonito, P.; Di Sessa, A. New Diagnostic Criteria for Hypertension in Children and Adolescents: Lights and Shadows. Children 2020, 7, 196. [Google Scholar] [CrossRef] [PubMed]
- Rabi, D.M.; McBrien, K.A.; Sapir-Pichhadze, R.; Nakhla, M.; Ahmed, S.B.; Dumanski, S.M.; Butalia, S.; Leung, A.A.; Harris, K.C.; Cloutier, L.; et al. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can. J. Cardiol. 2020, 36, 596–624. [Google Scholar] [CrossRef] [PubMed]
- Hertiš, T.; Petek, T.; Marčun Varda, N. The Prevalence of Elevated Blood Pressure in a Sample of Slovene Children and Adolescents: A Pilot Study. Slov. J. Public Health 2018, 57, 72–80. [Google Scholar] [CrossRef] [PubMed]
- Thomas, J.; Stonebrook, E.; Kallash, M. Pediatric Hypertension: Review of the Definition, Diagnosis, and Initial Management. Int. J. Pediatr. Adolesc. Med. 2022, 9, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Blanchette, E.; Flynn, J.T. Implications of the 2017 AAP Clinical Practice Guidelines for Management of Hypertension in Children and Adolescents: A Review. Curr. Hypertens. Rep. 2019, 21, 35. [Google Scholar] [CrossRef] [PubMed]
- Flynn, J.T.; Kaelber, D.C.; Baker-Smith, C.M.; Blowey, D.; Carroll, A.E.; Daniels, S.R.; De Ferranti, S.D.; Dionne, J.M.; Falkner, B.; Flinn, S.K.; et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017, 140, e20171904. [Google Scholar] [CrossRef] [PubMed]
- Sabri, M.; Gheissari, A.; Mansourian, M.; Mohammadifard, N.; Sarrafzadegan, N. Essential Hypertension in Children, a Growing Worldwide Problem. J. Res. Med. Sci. 2019, 24, 109. [Google Scholar] [CrossRef] [PubMed]
- Hong, Y.M. Atherosclerotic Cardiovascular Disease Beginning in Childhood. Korean Circ. J. 2010, 40, 1. [Google Scholar] [CrossRef] [PubMed]
- Falkner, B. Hypertension in Children and Adolescents: Epidemiology and Natural History. Pediatr. Nephrol. 2010, 25, 1219–1224. [Google Scholar] [CrossRef] [PubMed]
- Ranasinghe, P.; Cooray, D.N.; Jayawardena, R.; Katulanda, P. The Influence of Family History of Hypertension on Disease Prevalence and Associated Metabolic Risk Factors among Sri Lankan Adults. BMC Public Health 2015, 15, 576. [Google Scholar] [CrossRef] [PubMed]
- Charan, J.; Buch, N.; Goyal, J.P.; Kumar, N.; Parmar, I.; Shah, V.B. Prevalence of Hypertension in School Going Children of Surat City, Western India. J. Cardiovasc. Dis. Res. 2011, 2, 228–232. [Google Scholar] [CrossRef] [PubMed]
- Papandreou, D.; Stamou, M.; Malindretos, P.; Rousso, I.; Mavromichalis, I. Prevalence of Hypertension and Association of Dietary Mineral Intake with Blood Pressure in Healthy Schoolchildren from Northern Greece Aged 7–15 Years. Ann. Nutr. Metab. 2007, 51, 471–476. [Google Scholar] [CrossRef] [PubMed]
- Pagi, R.; Yadin, O.; Wesseling-Perry, K.; Norris, K.; Laster, M.L. Racial-Ethnic Diversity in Ambulatory Blood Pressure Monitoring in Children with Chronic Kidney Disease. Pediatr. Nephrol. 2023, 38, 819–827. [Google Scholar] [CrossRef] [PubMed]
- Hanevold, C.D. Racial-Ethnic Disparities in Childhood Hypertension. Pediatr. Nephrol. 2023, 38, 619–623. [Google Scholar] [CrossRef] [PubMed]
- Turer, C.B.; Brady, T.M.; De Ferranti, S.D. Obesity, Hypertension, and Dyslipidemia in Childhood Are Key Modifiable Antecedents of Adult Cardiovascular Disease: A Call to Action. Circulation 2018, 137, 1256–1259. [Google Scholar] [CrossRef] [PubMed]
- Kubota, M. Hyperuricemia in Children and Adolescents: Present Knowledge and Future Directions. J. Nutr. Metabol. 2019, 2019, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Kubińska, Z.; Mysula, I.; Zaworski, K.; Pocztarska-Głos, A. Physioprophylaxisin Physiotherapy with Emphasis on Physical Activity. Galician Med. J. 2019, 26, E201923. [Google Scholar] [CrossRef]
- Morton, K.; Heindl, B.; Clarkson, S.; Bittner, V. Primordial Prevention of Atherosclerotic Cardiovascular Disease: A Review of the Literature. J. Cardiopulm. Rehabil. Prev. 2022, 42, 389–396. [Google Scholar] [CrossRef] [PubMed]
- Gillman, M.W. Primordial Prevention of Cardiovascular Disease. Circulation 2015, 131, 599–601. [Google Scholar] [CrossRef] [PubMed]
- Lloyd-Jones, D.M.; Allen, N.B.; Anderson, C.A.M.; Black, T.; Brewer, L.C.; Foraker, R.E.; Grandner, M.A.; Lavretsky, H.; Perak, A.M.; Sharma, G.; et al. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation 2022, 146, E18–E43. [Google Scholar] [CrossRef] [PubMed]
- D’Ascenzi, F.; Sciaccaluga, C.; Cameli, M.; Cecere, A.; Ciccone, M.M.; Di Francesco, S.; Ganau, A.; Imbalzano, E.; Liga, R.; Palermo, P.; et al. When Should Cardiovascular Prevention Begin? The Importance of Antenatal, Perinatal and Primordial Prevention. Eur. J. Prev. Cardiol. 2021, 28, 361–369. [Google Scholar] [CrossRef] [PubMed]
- Chatmethakul, T.; Roghair, R.D. Risk of Hypertension Following Perinatal Adversity: IUGR and Prematurity. J. Endocrinol. 2019, 242, T21–T32. [Google Scholar] [CrossRef] [PubMed]
- Norton, D.E.; Froelicher, E.S.; Waters, C.M.; Carrieri-Kohlman, V. Parental Influence on Models of Primary Prevention of Cardiovascular Disease in Children. Eur. J. Cardiovasc. Nurs. 2003, 2, 311–322. [Google Scholar] [CrossRef] [PubMed]
- Myette, R.L.; Flynn, J.T. The Ongoing Impact of Obesity on Childhood Hypertension. Pediatr. Nephrol. 2024, 39, 2337–2346. [Google Scholar] [CrossRef] [PubMed]
- Brady, T.M. Obesity-Related Hypertension in Children. Front. Pediatr. 2017, 5, 197. [Google Scholar] [CrossRef] [PubMed]
- Capra, M.; Monopoli, D.; Decarolis, N.; Giudice, A.; Stanyevic, B.; Esposito, S.; Biasucci, G. Dietary Models and Cardiovascular Risk Prevention in Pediatric Patients. Nutrients 2023, 15, 3664. [Google Scholar] [CrossRef] [PubMed]
- Falkner, B.; Sherif, K.; Michel, S.; Kushner, H. Dietary Nutrients and Blood Pressure in Urban Minority Adolescents at Risk for Hypertension. Arch. Pediatr. Adolesc. Med. 2000, 154, 918. [Google Scholar] [CrossRef] [PubMed]
- Lindberg, J.; Norman, M.; Westrup, B.; Domellöf, M.; Berglund, S.K. Lower Systolic Blood Pressure at Age 7 y in Low-Birth-Weight Children Who Received Iron Supplements in Infancy: Results from a Randomized Controlled Trial. Am. J. Clin. Nutr. 2017, 106, 475–480. [Google Scholar] [CrossRef] [PubMed]
- Abboud, M. Vitamin D Supplementation and Blood Pressure in Children and Adolescents: A Systematic Review and Meta-Analysis. Nutrients 2020, 12, 1163. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Wang, Y.; Li, W.; Zhang, Y.; Cao, R.; Peng, X.; Zhang, J.; Liu, K.; Han, M.; Fu, L. Physical Activity and Eating Behaviors Patterns Associated with High Blood Pressure among Chinese Children and Adolescents. BMC Public Health 2023, 23, 1516. [Google Scholar] [CrossRef] [PubMed]
- Bird, C.; Michie, C. Measuring Blood Pressure in Children. BMJ 2008, 336, 1321. [Google Scholar] [CrossRef] [PubMed]
- Craig, A.; Ware, L.J.; Mapanga, W.; Norris, S.A. A Comparison of Paediatric Hypertension Clinical Practice Guidelines and Their Ability to Predict Adult Hypertension in an African Birth Cohort. J. Hum. Hypertens. 2022, 37, 455–462. [Google Scholar] [CrossRef] [PubMed]
- Álvarez, J.; Aguilar, F.; Lurbe, E. Blood Pressure Measurement in Children and Adolescents: Key Element in the Evaluation of Arterial Hypertension. An. De Pediatría 2022, 96, 536.e1–536.e7. [Google Scholar] [CrossRef]
- Ivanova, E.; Ruzgienė, D.; Ažukaitis, K.; Jankauskienė, A. Pharmacological Treatment of Arterial Hypertension in Children and Adolescents in Lithuania. Int. J. Environ. Res. Public Health 2022, 19, 13949. [Google Scholar] [CrossRef] [PubMed]
- Močnik, M.; Marčun Varda, N. Cardiovascular Risk Factors in Children with Obesity, Preventive Diagnostics and Possible Interventions. Metabolites 2021, 11, 551. [Google Scholar] [CrossRef] [PubMed]
- Jamoulle, M. Quaternary Prevention: First, Do Not Harm. Rev. Bras. Med. Fam. Comunidade 2015, 10, 1–3. [Google Scholar] [CrossRef]
2016 European Society of Hypertension Guidelines | 2017 American Academy of Pediatrics Clinical Practice Guidelines | Hypertension Canada’s 2020 Guidelines | ||||
---|---|---|---|---|---|---|
<16 Years | ≥16 Years | <13 Years | ≥13 Years | 6–11 Years | 12–17 Years | |
Normal BP | <90th percentile | <130/85 mmHg | <90th percentile | <120/<80 mmHg | <95th percentile or <120/80 mmHg | <95th percentile or <130/85 mmHg |
Elevated BP | ≥90th to <95th percentile | 130–139/85–89 mmHg | ≥90th to < 95th percentile or 120–129/<80 mmHg (whichever is lower) | 120/<80 to 129/<80 mmHg | Not defined | Not defined |
Stage 1 hypertension | ≥95th to <99th percentile + 5 mmHg | 140–159/90–99 mmHg | ≥95th percentile to <95th percentile + 12 mmHg, or 130/80 to 139/89 mmHg (whichever is lower) | 130/80 to 139/89 mmHg | 95th–95th percentile + 12 mm Hg | |
Stage 2 hypertension | ≥99th percentile + 5 mmHg | 160–179/100–109 mmHg | ≥95th percentile + 12 mmHg, or ≥140/90 mmHg (whichever is lower) | ≥140/90 mmHg | >95th percentile + 12 mm Hg |
Type/Level of Prevention | Aim of Measures |
---|---|
Primordial | Control of single risk factors in a normal range (healthy lifestyle, body weight control) |
Primary | Prevention of disease (education focused on maintaining or restoring a healthy lifestyle) |
Secondary (early) | Detection of the disease in its early, asymptomatic stage (screening, medical treatment) |
Tertiary (late) | Preventing disease complications |
Quaternary | Preventing unnecessary or harmful medical activities (preventing unnecessary examinations, pharmacotherapy) |
Drug Category | Drug | Initial Daily Oral Dose | Maximum Daily Oral Dose | Dosing Interval | Recommended Age |
---|---|---|---|---|---|
ACE inhibitors | Benazepril | 0.2 mg/kg max: 10 mg | 0.6 mg/kg max: 40 mg | Once/day | ≥6 years |
Captopril | 0.05 mg/kg/dose (max: 40 mg) 0.5 mg/kg/dose | 6 mg/kg 6 mg/kg | Four times/day Three times/day | Babies Children | |
Enalapril | 0.08 mg/kg max: 5 mg | 0.6 mg/kg | Once or twice daily | ≥1 month | |
Fosinopril | 0.1–0.6 mg/kg max: 5 mg | 40 mg | Once/day | ≥6 years | |
Lisinopril | 0.07 mg/kg max: 5 mg | 0.6 mg/kg max: 40 mg/day | Once/day | ≥6 years | |
Ramipril | 1.6 mg/m2 | 6 mg/m2 | Once/day | ||
Angiotensin receptor blockers | Candesartan | 0.16–0.5 mg/kg | <50 kg: 16 mg >50 kg: 32 mg | Once/day | ≥1 year |
Irbesartan | 75 mg 150 mg | 150 mg 300 mg | Once/day | 6–12 years ≥13 years | |
Losartan | 0.7 mg/kg max: 50 mg | 1.4 mg/kg max: 100 mg | Once/day | ≥6 years | |
Olmesartan | <35 kg: 10 mg >35 mg: 20 mg | 20 mg 40 mg | Once/day | ≥6 years | |
Valsartan | 0.4 mg/kg | 40–80 mg | Once/day | ≥6 years | |
Beta-blockers | Atenolol | 0.5–1 mg/kg | 2 mg/kg max: 100 mg | Once or twice daily | |
Metoprolol | 0.5–1 mg/kg | 2 mg/kg | Once or twice daily | ||
Propranolol | 1 mg/kg | 4 mg/kg max: 640 mg | Twice or three times daily | ||
Diuretics | Chlorthalidone | 0.3 mg/kg | 2 mg/kg max: 50 mg | Once/day | Children |
Chlorothiazide | 10 mg/kg | 20 mg/kg max: 375 mg | Once or twice daily | Children | |
Hydrochlorothiazide | 1 mg/kg | 2 mg/kg max: 37.5 mg | Once or twice daily | Children | |
Amiloride | 0.4–0.6 mg/kg | 20 mg | Once/day | ||
Spironolactone | 1 mg/kg | 3.3 mg/kg max: 100 mg | Once or twice daily | ||
Furosemide | 0.5–2 mg/kg | 6 mg/kg | Once or twice daily | ||
Eplerenone | 25 mg | 100 mg | Once or twice daily | ||
Triamterene | 1–2 mg/kg | 3–4 mg/kg | |||
Calcium channel blockers | Amlodipine | 0.1 mg/kg 0.3 mg/kg | 5 mg 10 mg | Once/day | 1–5 years ≥6 years |
Felodipine | 2.5 mg | 10 mg | Once/day | ≥6 years | |
Isradipine | 0.05–0.1 mg/kg | 0.6 mg/kg max: 10 mg | Twice or three times daily | Children | |
Nifedipine | 0.25–0.5 mg/kg | 3 mg/kg max: 120 mg | Once or twice daily | ||
Alpha- and beta blockers | Labetalol | 1–3 mg/kg | 10–12 mg/kg max: 1200 mg | Once/day | |
Central alpha agonists | Clonidine | 0.2 mg/kg | 2.4 mg/kg | Twice/day | |
Peripheral alpha blockers | Doxazosin | 1 mg | 4 mg | Once/day | |
Prazosin | 0.05–0.1 mg/kg | 0.5 mg/kg | Three times/day | ||
Vasodilators | Hydralazine | 0.75 mg/kg | 7.5 mg/kg max: 200 mg | Four times/day | |
Minoxidil | 0.2 mg/kg | 50–100 mg | Once to three times daily |
Short-Term Complications | Long-Term Complications |
---|---|
Left ventricular hypertrophy | Persistent hypertension |
Vascular damage (endothelial dysfunction) | Cardiovascular disease |
Kidney damage (proteinuria, chronic kidney disease) | Metabolic syndrome |
Eye damage (hypertensive retinopathy) | Impaired cognitive function |
Cerebrovascular effects (very rare) | Psychosocial impact |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Močnik, M.; Marčun Varda, N. Preventive Cardiovascular Measures in Children with Elevated Blood Pressure. Life 2024, 14, 1001. https://doi.org/10.3390/life14081001
Močnik M, Marčun Varda N. Preventive Cardiovascular Measures in Children with Elevated Blood Pressure. Life. 2024; 14(8):1001. https://doi.org/10.3390/life14081001
Chicago/Turabian StyleMočnik, Mirjam, and Nataša Marčun Varda. 2024. "Preventive Cardiovascular Measures in Children with Elevated Blood Pressure" Life 14, no. 8: 1001. https://doi.org/10.3390/life14081001
APA StyleMočnik, M., & Marčun Varda, N. (2024). Preventive Cardiovascular Measures in Children with Elevated Blood Pressure. Life, 14(8), 1001. https://doi.org/10.3390/life14081001